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Abstract 
Background 
Subjective reports of insomnia and hypersomnia are common in bipolar disorder (BD).  It is unclear 
to what extent these relate to underlying circadian rhythm disorder (CRD).  
Aims 
To objectively assess sleep and CRD in a cohort of patients with BD. 
Methods 
46 patients with BD and 42 controls had comprehensive sleep/circadian rhythm assessment with 
respiratory sleep studies, prolonged accelerometry, sleep diaries, melatonin levels, alongside mood, 
psychosocial functioning and quality of life (QoL) questionnaires. 
Results 
23 (50%) of patients with BD had abnormal sleep, of who 12 (52%) had a CRD.  Patients with 
abnormal sleep had lower 24 hour melatonin secretion compared to controls and patients with 
normal sleep.  Abnormal sleep/CRD in BD was associated with impaired functioning and worse QoL. 
Conclusions 
BD is associated with high rates of abnormal sleep and CRD.  The association between these 
disorders, mood and functioning, and the direction of causality, warrants further investigation. 
 
Declaration of Interests 
None.  
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Introduction 
Subjective reports of sleep disturbance – both insomnia and hypersomnia – are described in all 
phases of bipolar disorder (BD), including remission (1-3) but with substantial variability in 
prevalence between studies.  A recent meta-analysis of studies objectively estimating sleep variables 
in remitted BD patients demonstrated prolonged total sleep time (TST), increased wakenings after 
sleep onset and reduced sleep efficiency (4).  This meta-analysis highlighted that there has also been 
little consistency in the way sleep and circadian rhythm has been measured and assessed.  Studies 
have used a range of actiwatches and algorithms for calculating sleep and wake estimates and 
utilised variable recording periods making comparisons across studies challenging.  There is a need 
for methodological improvements, including longer recordings to allow improved analysis of 
circadian rhythm measures.  Thus it is currently unknown what proportion of sleep disorder relates 
to a circadian rhythm disorder (CRD). Further, none of the published actigraphy studies in BD have 
performed respiratory sleep studies to screen for primary sleep disorders, such as obstructive sleep 
apnoea (OSA), that may additionally contribute to hypersomnia and sleep fragmentation.  The aim of 
this study was to describe the different sleep/wake phenotypes in an opportunistic cohort of 
patients with BD and age matched healthy controls with a comprehensive battery of objective and 
subjective assessments of sleep and circadian variables, including urinary melatonin levels and 
respiratory sleep studies analysis.  
 
Method 
Participants 
The study was approved by the National Research Ethics Service Committee North East - Newcastle 
& North Tyneside.  Outpatients with BD type I or II, in any mood state, were recruited from a 
research database, patient support groups, and NHS services in the North East of England. Healthy 
controls, matched by age and gender, were recruited from Newcastle University, local volunteer 
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databases and hospital staff and their families.  All participants provided written informed consent 
before taking part in the research.  Participants were 18 to 65 years, fluent in English and able to 
provide consent. Exclusion criteria were; Verbal IQ < 90 assessed with National Adult Reading Test 
(NART)(5), any significant medical or neurological disorder that might interfere with sleep or 
cognition, current alcohol or substance misuse disorder (defined with DSM IV criteria(6), current 
shift work and previous significant head injury. A BD diagnosis meeting DSM-IV criteria was 
confirmed using the Mini International Neuropsychological Interview (MINI)(7). Patients with BD 
were excluded if they had had any changes to their psychotropic medication in the previous 4 
weeks. Exclusion criteria for controls were personal or first degree relative history of a DSM IV Axis I 
disorder, prescribed psychotropic medications and any known sleep disorder. Additionally controls 
had to be psychiatrically well, confirmed by MINI interview, have a Hamilton Depression rating scale 
score (HAMD17) score <7, a Young Mania Rating Scale score (YMRS) <5, a Pittsburgh sleep quality 
index (PSQI) <5 and Epworth sleepiness scale (ESS) score <10.  
Overall study design 
The study was cross-sectional, with participants assessed over a three week period. 
Psychiatric Symptoms and Subjective Sleep Assessments 
Participants were assessed on days 1 and 21. A comprehensive battery of questionnaires and rating 
scales were used to assess mood, anxiety and functioning.  These included: the 17 item GRID-HAMD 
(8), Beck Depression Inventory (BDI) (9), YMRS (10), the State and Trait Anxiety Inventory (STAI) (11), 
the Functioning Assessment Short Test (FAST) (12).  Quality of life (QoL) was assessed with the BD 
specific scale, the QoL.BD (13).  Subjective sleep and circadian rhythm was assessed using: the 
Biological Rhythms Interview of Assessment in Neuropsychiatry (BRIAN) (14), the PSQI (15) and the 
ESS (16). A short version of the morningness/eveningness questionnaire (17) was also used on day 1 
of the study to assess chronotype. All medications used by the patients in the BD group were 
recorded.  
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Assessment for sleep apnoea 
A single night of home partial polysomnography, using the Embletta Gold Polygraphy System (Embla 
Systems, Bloomfield, USA), was used to screen for sleep apnoea. Respiratory events were scored 
according to the standard criteria of the American Association of Sleep Medicine (AASM) (18) and 
the apnoea hypopnoea index (AHI) and oxygen desaturation index (ODI) derived. An AHI of > 5/hr 
was considered abnormal and indicative of sleep apnoea. Severity was defined as mild (AHI 5-15), 
moderate (AHI 15 – 30) or severe (AHI >30).  
Assessment for Restless Leg Syndrome (RLS).  
Participants completed the Restless Legs Syndrome Rating Scale to assess for the presence and 
severity of RLS (19).  
Assessment of sleep wake cycle 
Subjects wore a triaxial wrist accelerometer (GENEActiv; Activinsights) on their non-dominant wrist 
for all 21 days of the study and completed a daily sleep log recording lights out, out of bed time and 
any daytime naps. The raw accelerometer data was analysed using an open source R package sleep 
detection algorithm GGIR that has demonstrated a high sensitivity and specificity to detect periods 
of sleep (20). The algorithm also utilises the sleep log to distinguish nocturnal sleep from daytime 
naps. As this algorithm is non-proprietary, open access and able to analyse raw accelerometer data 
recorded on any brand of accelerometer its use should facilitate direct comparisons of sleep 
estimates from future studies. The following variables were derived: sleep onset time, sleep offset 
time, TST, time in bed (TIB), sleep efficiency (defined as TST/TIB) and mean 24 hour sleep duration 
(defined as nocturnal sleep plus daytime naps). Intra-individual variability in sleep variables was 
defined by the between night standard deviation over the assessment period for individual 
participants. Correlation analysis was performed to check agreement between sleep logs and 
accelerometer derived sleep variables. The relative amplitude between day and night activity was 
calculated from mean acceleration during the least active 5 hours (L5) and most active 10 hours 
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(M10) according to previously published methods (21). Using both accelerometry derived sleep 
estimates and the visual sleep wake actograms produced by the algorithm participants were then 
identified as normal sleepers (6-10 hours sleep within 24 hours with a regular sleep wake cycle), 
short sleepers (<6 hours nocturnal sleep), long sleep (>10 hours sleep within 24 hours) and circadian 
rhythm disorder evidenced by either a delayed sleep phase, advanced sleep phase, an irregular sleep 
wake pattern or a non24 hour pattern in keeping with the circadian rhythm types within the 
International Classification of Sleep Disorder – 3rd edition (ICSD-3) (22). 
Melatonin Measurement 
To further explore possible mechanisms of circadian dysfunction 6-sulphatoxymelatonin (aMT6S) 
was measured. This metabolite of melatonin, was measured in urine over a 48 hour period, once 
during the first week of the study period and once during the third week of the study period with 
analysis as per previous published protocols (23).  
Statistical analysis 
All statistical analyses were performed using IBM SPSS statistical package version 22.  Normality of 
distribution of data was tested using the Shapiro-Wilk test.  Log10 or square root transformations 
were used where necessary to normalise the data.  Parametric tests were used unless the data 
remained non-normally distributed despite transformation when equivalent non-parametric tests 
were used.  A significance threshold of p< 0.05 was used for all analyses. 
 
Results 
Participants 
Eighty eight participants, 46 with BD (16 BD I and 30 BDII) and 42 controls, completed the study 
protocol and provided accelerometer data (mean 19.7 (SD 3.0) days). Table 1 shows the participant 
characteristics. Groups did not differ significantly with regard to age or gender but participants with 
BD had a greater body mass index (BMI), were more likely to be unemployed, and scored more 
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highly on mood and anxiety ratings and lower on quality of life. Twenty one participants with BD 
scored > 8 on the HAMD17 (range 8 -35), but none of the patients were considered clinically to be 
manic or hypomanic for the duration of the study (YMRS range 0-10).   
Subjective description of sleep 
On the PSQI, which is validated for identifying clinically significant sleep disturbance, patients with 
BD scored on average 6.4 points higher than the healthy controls (Table 1), with 30 (65.2%) scoring 
≥5, indicative of some form of sleep disturbance (Note that a PSQI of ≥5 was an exclusion criteria for 
healthy controls). Many patients with BD described subjective problems with their sleep.  Their 
average score across the three HAMD17 sleep items was 2.13 (SD 1.9), with 12 (26.1%) of patients 
scoring ≥4.  Nine BD patients scored > 10 on the ESS indicating some excessive daytime sleepiness.  
In terms of chronotype, the BD group contained more participants with an evening preference than 
the control group but the difference was not statistically significant (chi squared; 4.449, p=0.108). 
Sleep Apnoea 
Forty one of 46 participants with BD and 40 of the 42 controls completed the overnight partial 
polysomnography providing good quality respiratory data. Significantly more participants with BD 
than controls had OSA (BD n=12 (29%), controls n=4 (10%), chi squared; 4.742, p=0.029). Four 
participants with BD had moderately severe OSA (AHI 15-30) but no participant in either group had 
severe sleep apnoea (AHI > 30). One participant with BD was already on continuous positive airways 
pressure (CPAP) treatment for known OSA and was therefore counted as AHI < 5 and hence with 
‘normal’ sleep.  
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Restless Leg Syndrome 
Two participants with BD, but no controls, reported moderate or severe restless legs symptoms.  
Accelerometry defined sleep/wake cycles 
Compliance with the accelerometry was very good with the mean number of nights of data collected 
being 20.1 for controls and 19.2 for the BD group. Accelerometry measures showed participants with 
BD to spend significantly longer time in bed, have significantly longer nocturnal sleep time and also 
more unstable and variable sleep wake patterns, alongside longer daytime napping periods, than 
those in the control group (see supplementary Table 1). Compared to controls participants with BD 
spent around 51 minutes per night longer in bed, spent 24 mins longer asleep at night and had lower 
sleep efficiency. Daytime napping/sedentary behaviour was also on average significantly longer by 
29 mins/day in participants with BD. The relative amplitude between the most active 10 hours and 
least active 5 hours was significantly lower in the participants with BD than the controls driven 
primarily by significantly lower M10 activity. The intra-subject variability in all sleep variables was 
significantly greater in the participants with BD, indicating instability in sleep/wake patterns 
compared to controls. 
Visual representations of typical actograms are shown in figure 1. Using the definitions as described 
above 23 of the BD patients had normal sleep and 23 had abnormal sleep length or CRD. Four (2.2%) 
were short nocturnal sleepers and 14 (30.4%) were long sleepers over each 24 hour period.  It is 
however important to note that if naps and sedentary behaviour during the day are included, no 
patient with BD ‘slept’ for less than 6 hours per 24 hours period. Similarly, of the long sleepers none 
slept for more than 10 hours in a 24 hour period when daytime naps and sedentary behaviour were 
excluded i.e. no BD patient had > 10 hours nocturnal sleep. Twelve (26.1%) had CRD including 
delayed sleep phase pattern (n=3), advanced sleep phase pattern (n=1), irregular sleep/wake phase 
(n=3) non-24 hour sleep/wake phase disorder (n=4) and circadian sleep-wake disorder not otherwise 
specified (n=1). This compared with just four control participants with CRD, one with an advanced 
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sleep phase and three with delayed sleep phase.  There was significant overlap between the various 
sleep and circadian disorders as shown in figure 2.  Two of the four BD patients who were short 
sleepers and 6 of the 14 long sleepers had evidence of CRD.  OSA was also a potential explanation of 
long sleep in 5 patients with BD but an additional 3 long sleepers did not complete the partial 
oximetry so their sleep apnoea status was unknown.  
Melatonin assays 
To further evaluate whether the sleep/wake cycles were synchronised to the body clock phase, we 
measured 48 hour melatonin rhythms on two occasions. Thirty nine controls and 38 BD participants 
provided at least one urine collection that had a clear melatonin rhythm assessed with cosinor 
analysis.  An additional 2 participants with BD provided good samples but had a 24 hour aMT6s 
output that was too low to detect a rhythm (<3µg/24 hours). Fifty seven (n=30 controls; n=27 BD) 
participants provided 2 urine samples allowing a period to be calculated. Two participants in the 
control group and 5 BD participants had a non-24 hour melatonin period (defined as > 24.2 hours or 
< 23.8 hours). Controls demonstrated a significantly greater aMT6s secretion( μg/24 hours)  than the 
BD group (18.0 (SD=9.1) vs 12.8 (SD=8.5); Mann-Whitney; 476.0; p=0.003), a greater mesor (µg) 
(rhythm adjusted mean), controls 12.1 (SD 6.1) vs BD 9.0 (SD 6.0); t=2.56 (75), p=0.012 and 
amplitude (µg), controls 14.5 (SD 8.0) vs. BD 9.8 (SD 7.7); t= 3.03 (75), p=0.003. Control participants 
also differed from BD participants in that they demonstrated a significantly earlier mean acrophase 
(hours)(time of peak aMT6s concentration) which was on average 1 hour 26 minutes earlier, controls 
3.24 (SD=1.88) vs BD 4.67 (SD=2.23); Mann-Whitney U; 476.0, p=0.004). The later acrophase in the 
BD group is indicative of a delayed biological rhythm compared to the controls, which was in keeping 
with the numerically greater proportion of evening chronotypes in the BD group (see Table 1).  
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Comparison of mood, sleep, function, QoL and melatonin in normal and abnormal sleeping BD 
patients.   
Differences in mood, anxiety, psychosocial function and QoL were explored within the BD group 
comparing those with accelerometer defined normal (n=23) and abnormal sleep (n=23) (table 2). 
There were no statistically significant differences in age, BMI, numbers with OSA or mean AHI, mood 
or anxiety between the groups. Abnormal sleepers subjectively rated their sleep as lower quality 
than normal sleepers on the PSQI although it is noteworthy that normal sleeping BD participants still 
scored in the clinically significant range for poor sleep quality(>5).  BRIAN scores were also 
significantly greater in abnormal compared to normal sleepers indicating greater difficulty 
maintaining good 24 hour rhythms.  However, there was no significant difference in daytime 
sleepiness scores measured on the ESS with both groups scoring in the normal range (ESS < 10).  
While mood ratings did not differ between normal and abnormal sleeping groups, there was a 
significant correlation between both HAMD17 and BDI scores and PSQI total score in the BD group 
(Spearmans rank order correlation r2(45) = 0.564, p<0.001 r2(45) = 0.598, p<0.001 respectively), 
though no correlation between objective actigraphy measures and mood.  There was, however, 
significantly poorer psychosocial functioning (t-test; 3.033; p<0.004) and lower QoL (t-test; -2.495; 
p=0.016) in abnormal versus normal sleeping patients with BD.  These differences remained when 
covarying for either HAMD17 (FAST, F=6.502 df = 1,43,  p=0.014; QoL.BD, F=6.436 df= 1, 43, p=0.015) 
or BDI (FAST, F = 7.527, p=0.009;  QoL.BD, F=8.839, p=0.005). The aMT6s 24 hour secretion also 
differed significantly within the BD group. BD participants with normal sleeping patterns 
demonstrated significantly greater 24 hour aMT6s secretion than abnormal sleeping participants 
(table 2), but did not differ from normal sleeping controls (BD 15.8 (SD 9.1) vs controls 17.5 (8.3) 
(Mann-Whitney U 266.0; p=0.367).  
 
Discussion 
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This is the most comprehensive study to date to assess sleep and CRD in patients with BD compared 
to controls.  Of the patients with abnormal sleep, a high proportion had CRD (26.1%) and there was 
considerable overlap between different sleep and circadian rhythm disorders.  Abnormality in 
circadian rhythm in BD was further demonstrated in the BD group by significant differences in 
melatonin secretion compared to healthy controls, particularly a decreased 24 hour output that was 
seen in the patients with abnormal sleep patterns.  Those BD patients with abnormal sleep had 
similar mood symptoms to those with normal sleep but less stable biological rhythms, worse 
psychosocial functioning and reduced QoL.   
The patients with BD in our study spent longer in bed, had more fragmented sleep and had more 
unstable and irregular sleep wake patterns. However we were also able to show different sleep 
phenotypes within individual participants. It was possible to determine that within the BD group, 23 
retained normal sleep wake patterns with a stable sleep wake pattern and total sleep time between 
6 and 10 hours. However 23 had clearly abnormal sleep with striking circadian dysrhythmia in 12 of 
the patients.  Although a number of previous studies have reported different patterns of sleep 
disturbance in BD, these have usually relied on only short periods of sleep diary or accelerometry 
data to assess the sleep/wake cycle.  Two different studies, each with just 19 BD patients compared 
group actigraphy variables over periods of 5 and 7 days respectively with controls, but did not define 
different sleep phenotypes between individual BD subjects but simply reported mean activity levels 
(24, 25).  One problem with the detection of CRDs is that patients may appear to have either an 
insomnia or hypersomnia pattern if the period of recording is too short and this is particularly true of 
a non-24 hour period disorder.  The recently revised ICSD-3 diagnostic criteria for this disorder 
stipulate at least 2 weeks of sleep logs and accelerometry should be performed to make the 
diagnosis (22).  Our data also supports this view given the high rate of patients with subjective 
descriptions of insomnia (as captured by the HAMD sleep items) while objective accelerometry data 
showed a low rate of short sleepers. Nine of the 12 patients who had a CRD scored the maximum of 
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2 on at least one of the HAMD sleep items suggesting many of the patients complaining of ‘insomnia’ 
actually have a CRD.   
There is increasing evidence for an intrinsic circadian rhythm dysfunction within a number of 
psychiatric disorders and some previous studies of melatonin levels in BD patients have shown 
reduced melatonin compared to controls as well as a later onset, however others have not shown 
any difference in light suppression response compared to controls(26-32). Repeated measurements 
are required to look at the period to estimate whether it is near 24 or longer and previous studies 
have not reported this. In our study, between group comparison of patients and controls showed 
both reduced melatonin output and a delayed acrophase (time of peak melatonin concentration) 
within BD compared to controls. However the differences were most marked in those with abnormal 
sleep and/or circadian rhythm where total amount of melatonin was significantly lower than those 
BD patients with normal sleep wake rhythms. There could be a number of potential reasons. Those 
with fragmented sleep may have abnormal light exposure, be in rooms with increased light levels or 
have light on during the night that suppresses melatonin output. Alternatively, a subset of BD 
patients could have an intrinsic circadian rhythm abnormality although all the controls and the 
majority of patients with BD had a normal pattern and timing of melatonin secretion, even some 
with abnormal accelerometry data. Some of those who reported fragmented night sleep had very 
low melatonin levels of <3ug/ml and this may provide a mechanistic explanation for the failure to 
consolidate night sleep for some and this may provide a therapeutic target. 
Overnight respiratory sleep studies analysis showed mild or moderately severe OSA in 29% of 
patients with BD compared to 10% of controls. There is increasing recognition that secondary 
consequences of inactivity, weight gain and metabolic syndrome possibly related to medication all 
increase the risk of conditions such as OSA in those with psychiatric disease.  As expected the BD 
group had an increased BMI compared to the control group.  OSA will fragment night sleep and 
contribute to daytime sleepiness, sedentary behaviour and potentially hypersomnia.  Indeed nearly 
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half of the patients with OSA were also rated as long sleepers.  While the sample of patients with BD 
was not an epidemiological one, the prevalence of OSA of 29% in our sample, is consistent with 
previous research (33, 34) and highlights the need for screening and treatment of OSA in this patient 
group given the association between OSA and serious cardiovascular morbidity (35).  
Those participants with BD with any cause of abnormal sleep had significantly worse psychosocial 
functioning and quality of life compared to those with normal sleep. The differences between groups 
remained after covarying for HAMD17 and BDI suggesting that accelerometry defined abnormal sleep 
was associated with lower function and QoL independently of mood.  It is noteworthy that although 
we found a moderate correlation between mood and subjective sleep quality measured on the PSQI 
we found no differences in mood scores between the groups of normal and abnormal BD sleepers 
defined by accelerometry. This may be because subjective and objective assessments measure 
different dimensions of sleep. Other studies have found associations between disturbed sleep and 
mood (36, 37) but both these studies used subjective sleep diaries to assess sleep function.  The 
impact of targeting specific sleep problems therapeutically on the course of BD needs to be 
examined further. A preliminary randomised controlled trial assessed the effects of cognitive 
behavioural therapy for insomnia in patients with BD and shown that not only was it possible to 
improve sleep efficiency and decrease the severity of insomnia, but time in episode of mood 
disturbance decreased (38).  
Strengths of the study include a well characterised group, multiple measures of mood and 
comprehensive measures of sleep and circadian rhythm across 21 days. The raw accelerometry data 
was analysed on an open access algorithm meaning future data sets can use identical analysis 
methodology thereby making different datasets directly comparable. 
Weaknesses of the study include a lack of the gold standard measure of sleep using video 
polysomnography. However this was a field study and it was felt that studying patients with partial 
polysomnography in their own homes would increase compliance and the main aim of the home 
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sleep study was to screen for all forms of sleep disordered breathing. The sample was also 
opportunistic with a potential bias for over-representation of patients with BD and sleep disorders, 
while controls were screened out if they suffered significant sleep problems.  A larger, more 
representative, sample size would have allowed more accurate assessment of the prevalence of 
sleep and circadian disorders as well as greater sub group analysis of the differential effect of the 
different disorders. 
In conclusion we have found that many patients with BD that have sleep disorders have a CRD 
and/or OSA.  BD participants with abnormal sleep had lower function and quality of life which was 
not accounted for by lower mood. Abnormal sleep in BD is also characterised by reduced 24 hour 
melatonin secretion compared to both healthy controls and those with BD and normal sleep. There 
is a need for the use of objective markers of the sleep wake cycle and respiratory function to 
accurately determine different sleep patterns within clinical populations and assess the impact of 
specific therapies targeted at these sleep and circadian disorders on long term outcomes of the 
psychiatric disorders. 
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Table 1. Characteristics of Participants 
   Test Statistics 
 Controls (n=42) Bipolar Disorder 
(n=46) 
Χ2 (df) Mann 
Whitney U 
p 
Female Gender n (%) 29 (69) 31 (67.4) 0.028 (1)  0.868 
Age years: mean (SD) 
(Range) 
42.5 (11.9) 
(19-64) 
46.8 (11.1) 
(23-64) 
 768.0  0.098 
BMI  mean: kg/m2 (SD) 
(Range) 
25.6 (4.8) 
(19.5-39.7) 
30.0 (6.7) 
(21.0-52.0) 
 538.0 0.001 
Currently Employed, n (%) 34 (81) 23 (50) 9.218 (1)  0.002 
Chronotype n (%) 
Morning 
Evening 
Neither Type 
 
19 (45.2) 
3 (7.1) 
20 (47.6) 
 
14 (30.4) 
10 (21.7) 
22 (47.8) 
 
4.449 (2) 
  
0.108 
HAM-D17 mean (SD) 
(Range)  
0.3 (0.6)  
(0-2) 
9.1 (7.2) 
(0-35) 
 49.0 <0.001 
BDI (SD)  
(Range) 
0.6 (1.6)  
(0-9) 
12.2 (11.5) 
(0-49) 
 127.5 <0.001 
YMRS mean (SD) 
(Range) 
0.1 (0.4) 
(0-2) 
0.9 (2.2) 
(0-10) 
 839.0 0.075 
STAI-S (SD) 
(Range) 
23.6 (4.0) 
(20-34) 
35.1 (12.8) 
(20-73) 
 345.5 p<0.001 
STAI-T 
(Range) 
24.6 (7.1) 
(20-54) 
44.0 (14.7) 
(21-77) 
 206.0 p<0.001 
PSQI Global score mean (SD) 
(Range) 
2.2 (1.3) 
(0-4) 
8.6 (4.6) 
(1-18) 
 138.5 <0.001 
ESS mean (SD) 
(Range) 
3.8 (2.5) 
(0-9) 
6.2 (4.9) 
(0-21) 
 680.5 0.016 
BRIAN mean (SD) 
(Range) 
20.4 (3.2) 
(18-30) 
40.1 (13.6) 
(18-65) 
 122.500 <0.001 
FAST mean (SD) 
(Range) 
3.9 (6.2) 
(0-22) 
23.2 (17.4) 
(0-72) 
 211.500 <0.001 
QoL.BD mean (SD) 
Range  
215.3 (20.2) 
(162-263) 
157.7 (39.5) 
(50-235) 
 167.500 <0.001 
SD = Standard Deviation, df = degrees of freedom, BMI = body mass index, HAM-D17 = 17 item Hamilton Depression Rating 
Scale, BDI = Beck Depression Inventory, YMRS = Young Mania Rating Scale, STAI- S/T = State and Trait Anxiety Inventory- 
State/Trait, PSQI = Pittsburgh Sleep Quality Index, ESS = Epworth Sleepiness Scale, BRIAN = Biological Rhythms Interview of 
Assessment in Neuropsychiatry, FAST = Functional Assessment Short Test, Qol.BD = Quality of Life in Bipolar Disorder 
Questionnaire Morning and evening chronotypes include both definite and moderate subtypes.  
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Table 2. BD normal vs. abnormal sleepers.  
 
 
 
 
 
 
 
BMI = body mass index, AHI = apnoea hypopnoea index, PSQI = Pittsburgh Sleep Quality Index, ESS = Epworth Sleepiness 
Scale, BRIAN = Biological Rhythms Interview of Assessment in Neuropsychiatry, FAST = Functional Assessment Short Test, 
Qol.BD = Quality of Life in Bipolar Disorder Questionnaire, HAMD17 = Hamilton Depression Rating Scale 17 item, BDI = Beck 
Depression Inventory, YMRS = Young Mania Rating Scale, ASRMS = Altman Self Rating Mania Scale, STAI-S/T = State and 
Trait Anxiety Inventory – State/trait, aMT6s = 6-sulphatoxymelatonin. 
 
  
 
 
Bipolar normal 
sleeper (n=23) 
Bipolar 
abnormal 
sleeper 
(n=23) 
Normal vs. abnormal test statistics  
 Mean (SD) Mean (SD) t (df) Mann 
Whitney U 
p 
Age (years)  45.6 (11.0)  47.9 (11.2)   229.5 0.441 
BMI (Kg/m2)  28.4 (4.5) 31.5 (8.1) 1.199 (44)  0.170 
AHI  6.3 (8.7) 4.3 (5.0)  198.0 0.754 
HAMD17 7.8 (7.0) 10.4 (7.3) 1.659 (44)  0.104 
BDI 10.0 (11.3) 14.4 (11.6) 1.770 (44)  0.084 
YMRS 1.4 (2.8) 0.4 (1.3)  225.5 0.216 
STAI-S 33.2 (14.4) 37.0 (10.9) 1.386 (44)  0.173 
STAI-T 40.5 (13.8) 47.3 (14.8) 1.611 (44)  0.114 
PSQI  6.9 (3.4) 10.4 (5.0) 2.733 (44)  0.009 
ESS 5.6 (3.7) 6.9 (5.8) 0.643(44)  0.524 
BRIAN 35.7 (13.6) 44.5 (12.3) 2.285 (44)  0.027 
FAST 16.7 (15.7) 29.7 (16.8) 3.033 (44)  0.004 
QoL.BD 171.4 (37.9) 143.9 (36.9) -2.495 (44)  0.016 
Melatonin (normal sleeper n=19, abnormal sleepers n=21).  
aMT6s (µg/24hr) 15.8 (9.1) 10.0 (7.0)  108.0 0.013 
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Supplementary Table 1. Summary Accelerometer Data 
   Test Statistic 
 Controls (n=42) Bipolar Disorder 
(n=46) 
t-test (df) Mann 
Whitney U 
p 
TIB hours (SD) 7.85 (0.77) 8.69 (1.48)  562.000 0.001 
Intra-subject variability in TIB 1.19 1.72 -3.016 (86)  0.003 
Nocturnal sleep time (SD) 6.92 (0.70) 7.33 (1.20)  664.000 0.012 
Intra-subject variability in 
nocturnal sleep time 
1.01 1.40 -3.386 (86)  0.001 
Sleep efficiency (SD) 0.88 (0.04) 0.85 (0.75)  707.000 0.030 
Intra-subject variability in sleep 
efficiency 
0.049 0.069 -2.960 (86)  0.004 
Daytime naps/sedentary 
behaviour (SD) 
1.47 (0.86) 1.95 (1.05) -2.246 (86)  0.027 
Intra-subject variability in daytime 
naps/ sedentary behaviour 
0.86 1.10 -2.336 (86)  0.022 
Intra-subject variability in sleep 
onset time (hours) 
0.99 1.42  730.000 0.056 
Intra-subject variability in sleep 
offset time (hours) 
1.29 2.24  694.000 0.023 
L5 (SD) 6.0 (2.8) 5.9 (1.9)   923.000 0.719 
M10 (SD) 47.8 (14.8) 37.8 (11.6) 3.508 (86)  0.001 
Relative amplitude between day 
and night activity (SD) 
0.77 (0.10) 0.71 (0.13)  698.000 0.025 
Mean acceleration (milli g) (SD) 30.77 (9.1) 23.77 (6.6) 4.119  <0.001 
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Figure 1.  
  
Figure 1. Actograms demonstrating the sleep wake cycle over 21 days and timing of aMT6s 
acrophase from 6 different sleep phenotypes.  
The blue diamonds represent the timing of the acrophase of aMT6s taken at two different time 
points over the 21 days of actigraphy.  
(a) Normal sleeper with a well entrained circadian rhythm. Mean nocturnal sleep duration = 6.9 
hours. 
(b) Short sleeper with a well entrained circadian rhythm. Mean sleep duration = 5.76 hours.   
(c) Long sleeper mean sleep duration = 10.95 hours. Note mildly irregular sleep/wake times and 
aMT6s period length =24.40 hours. 
(d) Advanced sleep phase with well entrained circadian rhythm. Mean sleep onset time = 20.25, 
mean nocturnal sleep duration = 7.23 hours.  
(e) Delayed sleep phase with well entrained circadian rhythm. Mean sleep onset time = 01:43, 
mean nocturnal sleep duration = 08:59 hours.  
(f) Non 24 hour sleep-wake rhythm. Actogram demonstrated an irregular sleep/wake cycle with 
evidence of free running sleep onset during the final 8 days. aMT6s period length = 24.40 
hours.  
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Figure 2. Sleep phenotypes and their overlap in the BD group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal sleepers = >6 & < 10 hours nocturnal sleep and no CRSD; Long sleepers = total 24 hour sleep 
> 10 hours; Short sleepers = nocturnal sleep < 6hours; CRSD = circadian rhythm sleep disorder; OSA = 
obstructive sleep apnoea.  
*3 of the participants in the long sleep only cohort and 2 of the normal sleepers did not complete the 
test for sleep apnoea.  
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